Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1236

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 10
Chunk 1236
---
 Non-Equity
    Incentive Plan Compensation ($)  
    Change
    in Pension Value and Nonqualified Deferred Compensation Earnings ($)  
    All
    Other Compensation ($)  
    Total
    ($) 
  
    Matthew
    Whalen 
     -  
         -  
     16,525  
                 -  
             -  
             -  
     - 
  
    Mathew
    Paul Del Giudice 
     -  
     -  
     69,775  
     -  
     -  
     -  
     69,775 
  
    Denil
    Shekhat 
     -  
     -  
     117,400  
     -  
     -  
     -  
     117,400 
  
    Edward
    MacPherson 
     -  
     -  
     69,775  
     -  
     -  
     -  
     69,775 
  
    Dr.
    Christopher Chapman 
     24,121  
     -  
     -  
     -  
     -  
     -  
     - 

    (1)
    The
    reported amounts represent the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards
    Board Account Standards Codification Topic 718, Stock Compensation, as modified or supplemented, or FASB ASC Topic 718. The assumptions
    used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 8 to our Consolidated
    Financial Statements for the year ended December 31, 2022 included in this Report.

Christopher
Chapman

On
April 28, 2023, we entered into an employment agreement with Dr. Chapman, as amended on August 28, 2023, and October 13, 2023, pursuant
to which Dr. Chapman served as our Executive Chairman. Dr. Chapman’s employment agreement, as amended, provided that his employment
would be on a part-time basis whereby Dr. Chapman would devote time and effort to the business and affairs of the company on an as needed
basis, and it further provides that such employment would be on an at-will basis